1
|
Demoor-Goldschmidt C, Supiot S, Mahé MA. [Breast cancer after radiotherapy: Risk factors and suggestion for breast delineation as an organ at risk in the prepuberal girl]. Cancer Radiother 2012; 16:140-51. [PMID: 22342367 DOI: 10.1016/j.canrad.2011.10.014] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2011] [Revised: 10/17/2011] [Accepted: 10/19/2011] [Indexed: 01/13/2023]
Abstract
Patients who survive a cancer occurring during childhood or young adulthood, treated with radiation, are at a very high risk of chronic sequelae and secondary tumours. To reduce this radioinduced morbidity and mortality, efforts are put on reducing the burden of the treatments and a long-term monitoring of these patients is progressively organized. We present a general review of the literature about the risk factors for developing a secondary breast cancer, which is the most frequent secondary tumour in this population. We suggest that contouring the prepubescent breast as an organ at risk may help predict the risk and reduce the dose to the breasts using modern radiotherapy techniques.
Collapse
Affiliation(s)
- C Demoor-Goldschmidt
- Service de radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, Nantes-Saint-Herblain, France.
| | | | | |
Collapse
|
2
|
[Hodgkin's disease and breast cancer: for which patients is there an association? A series from Institut Bergonié]. ACTA ACUST UNITED AC 2011; 40:284-90. [PMID: 22099978 DOI: 10.1016/j.gyobfe.2011.08.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2011] [Accepted: 07/12/2011] [Indexed: 11/23/2022]
Abstract
OBJECTIVE Breast cancer is the most frequent secondary tumor for women treated for Hodgkin's disease. It is important to study the risk factors associated to be able to adapt the monitoring of these women. PATIENTS AND METHODS This is a retrospective study from Institut Bergonié, a comprehensive French Cancer Center, concerning the women treated for Hodgkin's disease and having developed a breast cancer. RESULTS Among 328 women treated for Hodgkin's disease between January 1968 and December 1994, 20 patients developed 25 breast cancers. The average age of the patients during the irradiation was 24 years and the average period of occurrence of the cancer was 19 years. An irradiation of the chest wall and an under-diaphragmatic irradiation in doses of 40Gy are risk factors for the occurrence of breast cancer. A young age, less than 30, in the treatment of Hodgkin's disease tend to be significant. DISCUSSION AND CONCLUSION This population of women with a high risk of breast cancer thus has to benefit from an appropriate monitoring program, which is what we suggest setting up in the Institut Bergonié.
Collapse
|
3
|
Okines A, Thomson CS, Radstone CR, Horsman JM, Hancock BW. Second primary malignancies after treatment for malignant lymphoma. Br J Cancer 2005; 93:418-24. [PMID: 16106249 PMCID: PMC2361580 DOI: 10.1038/sj.bjc.6602731] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2005] [Revised: 07/06/2005] [Accepted: 07/06/2005] [Indexed: 11/25/2022] Open
Abstract
To determine the incidence and possible causes of second primary malignancies after treatment for Hodgkin's and Non-Hodgkin's lymphoma (HL and NHL). A cohort of 3764 consecutive patients diagnosed with HL or NHL between January 1970 and July 2001 was identified using the Sheffield Lymphoma Group database. A search was undertaken for all patients diagnosed with a subsequent primary malignancy. Two matched controls were identified for each case. Odds ratios were calculated to detect and quantify any risk factors in the cases compared to their matched controls. Mean follow-up for the cohort was 5.2 years. A total of 68 patients who developed second cancers at least 6 months after their primary diagnosis were identified, giving a crude incidence of 1.89% overall: 3.21% among the patients treated for HL, 1.32% in those treated for NHL. Most common were bronchial, breast, colorectal and haematological malignancies. High stage at diagnosis almost reached statistical significance in the analysis of just the NHL patients (odds ratio = 3.48; P = 0.068) after adjustment for other factors. Treatment modality was not statistically significant in any analysis. High stage at diagnosis of NHL may be a risk factor for developing a second primary cancer.
Collapse
Affiliation(s)
- A Okines
- YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK
| | - C S Thomson
- Trent Cancer Registry, 5 Old Fulwood Road, Sheffield S10 3TG, UK
| | - C R Radstone
- YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK
| | - J M Horsman
- YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK
| | - B W Hancock
- YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK
| |
Collapse
|
4
|
Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, DeLaat C, Fossati-Bellani F, Morgan E, Oberlin O, Reaman G, Ruymann FB, Tersak J, Meadows AT. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2004; 21:4386-94. [PMID: 14645429 DOI: 10.1200/jco.2003.11.059] [Citation(s) in RCA: 410] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE We present an update of a previously reported Late Effects Study Group cohort of 1,380 children with Hodgkin's disease (HD) diagnosed between 1955 and 1986 in patients aged 16 years or younger. We describe the pattern and incidence of subsequent neoplasms (SNs) occurring with extended follow-up. PATIENTS AND METHODS Median age at diagnosis of HD was 11.7 years (range, 0.3 to 16.9 years) and at last follow-up was 27.8 years. Median length of follow-up was 17.0 years. RESULTS An additional 103 SNs were ascertained (total SNs = 212). The cohort was at an 18.5-fold increased risk of developing SNs compared with the general population (standardized incidence ratio [SIR], 18.5, 95% CI, 15.6 to 21.7). The cumulative incidence of any second malignancy was 10.6% at 20 years, increasing to 26.3% at 30 years; and of solid malignancies was 7.3% at 20 years, increasing to 23.5% at 30 years. Breast cancer was the most common solid malignancy (SIR, 56.7). Other commonly occurring solid malignancies included thyroid cancer (SIR, 36.4), bone tumors (SIR, 37.1), and colorectal (SIR, 36.4), lung (SIR, 27.3), and gastric cancers (SIR, 63.9). Risk factors for solid tumors included young age at HD and radiation-based therapy. Thirty-two patients developed third neoplasms, with the cumulative incidence approaching 21% at 10 years from diagnosis of second malignancy. CONCLUSION Additional follow-up of this large cohort of HD survivors documents an increasing occurrence of known radiation-associated solid tumors, (breast and thyroid cancers), as well as emergence of epithelial neoplasms common in adults, (colon and lung cancers) at a younger age than expected in the general population, necessitating ongoing surveillance of this high risk population.
Collapse
Affiliation(s)
- Smita Bhatia
- City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010-3000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Abstract
The principal epidemiologic studies of ionizing radiation and skin cancer have all shown that radiation causes basal cell carcinoma but have not found dose-related excesses of squamous cell carcinoma or malignant melanoma. The Japanese atomic bomb study indicates that doses of radiation under about 1 Gy confer less risk per unit dose than higher doses do. All available studies show that skin cancer risk is greater from radiation exposure at young ages than at older ages. Finding few excess skin cancers among irradiated African-Americans as compared to Caucasians with a comparable dose indicates that skin susceptibility to ultraviolet exposure modifies the excess risk from ionizing radiation. Available evidence indicates that the excess risk of skin cancer lasts for 45 years or more following irradiation. Several studies indicate a risk of nonmelanoma skin cancer (NMSC) following cancer therapy; however, most of the studies reporting on NMSC have not distinguished between patients who received radiotherapy versus chemotherapy. Some, but not all, follow-up studies of cancer patients have reported excesses of malignant melanoma as second malignant neoplasms. It is not clear from the studies how much, if any, of the excess melanoma risk is attributable to radiotherapy.
Collapse
Affiliation(s)
- R E Shore
- Department of Environmental Medicine, New York University School of Medicine, New York, New York, USA.
| |
Collapse
|
6
|
Cellai E, Magrini SM, Masala G, Alterini R, Costantini AS, Rigacci L, Olmastroni L, Papi MG, Spediacci MA, Innocenti F, Bellesi G, Ferrini PR, Biti G. The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. Int J Radiat Oncol Biol Phys 2001; 49:1327-37. [PMID: 11286841 DOI: 10.1016/s0360-3016(00)01513-3] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
PURPOSE To quantify the incidence of second malignant tumors (SMT) as a whole and that of second "solid" tumors (SST) and leukemia (L) in a large series of 1524 Hodgkin's disease (HD) patients (pts) treated at the Florence University Hospital (UFH); to define the clinical and therapeutic features possibly related with SMT occurrence; to evaluate the consequences of SMT for the overall survival of the series studied and for the choice of the treatment of HD at presentation. METHODS AND MATERIALS From 1960 to 1991, 1524 pts with HD, Clinical Stage (CS) I--IV have been treated at the UFH. Overall treatment consisted of radiation alone (RT, 36%), chemotherapy alone (CHT, 21%), or both (RT + CHT, 43%). The cumulative probability (CP) of SMT, SST, and L was calculated for the whole series and for the different clinical and therapeutic subgroups, and the results compared with uni- and multivariate analysis ("internal" comparison, IC). Standardized incidence ratios (SIR) for different SMT types (estimated on the basis of gender, age, period specific incidence rates of the general population) have been also calculated ("external" comparison, EC). The impact of the SMT-related mortality on the survival of the entire series has been estimated. RESULTS A 14.9% 20-year CP of SMT was registered, along with a SIR of 2.04 (95% confidence interval [CI]: 1.2--2.5). Both IC and EC showed a statistically significant relationship between L incidence and treatment with CHT, alone or in combination with RT. A significant excess of breast cancers has been observed in RT-treated patients with longer follow-up (SIR, 2.9); an excess of other common SST (lung, non-Hodgkin's lymphomas) is evident in pts treated with either RT, RT + CHT, or CHT. The actuarial long-term survival of the series would have been better of about 3%, in absence of the SMT mortality possibly due to HD treatment, which is almost equally divided between patients treated with RT alone, CHT alone, and RT + CHT. CONCLUSIONS SMT represent an important late event in HD long-term survivors. The relationship between L and treatment with CHT seems to be the most clearly defined. The effect of SMT on the survival of the entire series, although not negligible, does not seem to justify by itself substantial alterations in the current standards for the treatment of HD at presentation.
Collapse
Affiliation(s)
- E Cellai
- Department of Radiation Oncology, Florence University Hospital, Florence, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Deutsch M, Gerszten K, Bloomer WD, Avisar E. Lumpectomy and breast irradiation for breast cancer arising after previous radiotherapy for Hodgkin's disease or lymphoma. Am J Clin Oncol 2001; 24:33-4. [PMID: 11232946 DOI: 10.1097/00000421-200102000-00005] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Twelve women treated with radiotherapy with or without chemotherapy for Hodgkin's disease (11 patients) and non-Hodgkin's lymphoma (1 patient) and in whom breast cancer subsequently developed 10 to 29 years later were treated with lumpectomy and breast irradiation. 5,000 cGy/25-30 fractions to the whole breast and 900 cGy to 1.000 cGy/5 boost to the operative area. Six also received adjuvant chemotherapy for breast cancer. Breast irradiation was well tolerated without any unusual acute or chronic sequelae. All women had a good to excellent cosmetic result. Ten women are alive and well 1 to 174 months (median: 46) from completion of breast irradiation. Two women died with distant metastasis but without local recurrence. Breast conservation therapy with radiotherapy is not contraindicated in the woman who has previously been treated with radiotherapy for Hodgkin's disease or lymphoma.
Collapse
Affiliation(s)
- M Deutsch
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
| | | | | | | |
Collapse
|
8
|
Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev 2000; 26:291-302. [PMID: 10913384 DOI: 10.1053/ctrv.2000.0174] [Citation(s) in RCA: 90] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Radiation is commonly used to treat early-stage Hodgkin's disease. As the risk of recurrent Hodgkin's disease decreases as time from treatment elapses, the risk of radiation-induced breast cancer rises. Women irradiated between the time of puberty and the age of 30 are at the highest risk. The median time to breast cancer following radiation in this age group is approximately 15 years, usually when women are aged between 30 and 40, and often before regular breast screening is implemented. Risk factors associated with breast cancer development include age at irradiation, time since treatment and the radiation dose received. Current screening for breast cancer after Hodgkin's disease is inconsistent. In this article we review breast development, mechanisms of radiation-induced carcinogenesis, and findings from retrospective studies on Hodgkin's disease and breast cancer. We also review future considerations of management, including assessment of risk awareness in these women, guidelines for follow-up and screening, and chemoprevention both during and after treatment of Hodgkin's disease. The literature reviewed was obtained from Medline using the key words: breast cancer, Hodgkin's disease and radiation-induced cancer. The search was limited to English language literature. Other sources include reference lists in books and published papers.
Collapse
Affiliation(s)
- M Clemons
- Department of Medical Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto M5G 2M9, Canada
| | | | | |
Collapse
|
9
|
Vuong T, Parker W, Patrocinio HJ, Fava P, Parmar D, Evans MD, Freeman CR. An alternative mantle irradiation technique using 3D CT- based treatment planning for female patients with Hodgkin's disease. Int J Radiat Oncol Biol Phys 2000; 47:739-48. [PMID: 10837959 DOI: 10.1016/s0360-3016(00)00438-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
PURPOSE For female patients, radiotherapy treatment for Hodgkin's disease invariably results in the irradiation of breast tissue that may lead to radiation induced secondary cancers. The risk for secondary breast cancer is correlated with dose. We have developed a technique in an attempt to increase breast sparing during mantle field irradiation for female patients. MATERIAL AND METHODS To minimize the irradiated breast volume, a virtual simulation technique making use of a Styrofoam breast immobilization board has been developed whereby the patient lies prone with the breasts positioned in grooves within the board. The breast position is adjusted using Styrofoam wedges, and breast placement is verified using an AP CT-pilot view. A CT scan of the neck and thoracic regions is taken, and the lymph nodes, breast volume and critical structures are outlined. Virtual simulation of the mantle fields (typically AP/PA isocentric beams) is performed, and beam blocks are drawn on the digitally reconstructed radiographs (DRR) generated by the virtual simulation package. The shielding is designed to allow adequate margins around the lymph nodes while maximizing shielding of the lung and breast tissues. The para-aortic fields are also easily determined through virtual simulation, where multi-planar reconstructions (MPR) and 3D renderings of the patient's CT data are used to determine the field limits and beam gaps. In addition to allowing for the geometric optimization of the positioning of the breasts under the lung shields, the virtual simulation technique provides the necessary information for a 3D dosimetric analysis, including dose-volume histograms (DVHs) of the irradiated breast volume. RESULTS The 3D breast sparing technique was qualitatively and quantitatively compared to non-CT-based techniques and other 3D techniques currently available to assess the protection of the breasts. In a preliminary analysis, virtual simulation images (DRRs, 3D rendering and multi-planar reconstruction) demonstrated the advantage of using the breast sparing technique. A further analysis of DVHs showed a reduction of at least 50% in the volume of breast tissue irradiated when using the breast positioning board and virtual simulation as compared to the conventional simulation techniques where a breast immobilization board was not used. CONCLUSIONS The use of a breast immobilization board and of a virtual simulation technique is recommended for the planning and treatment of female patients with Hodgkin's disease. DVH analysis has shown that this leads to a decrease in the volume of breast irradiated. It is hoped that this approach will reduce the risk of secondary breast malignancies in female patients with Hodgkin's disease.
Collapse
Affiliation(s)
- T Vuong
- Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
| | | | | | | | | | | | | |
Collapse
|
10
|
Wolden SL, Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT. Management of breast cancer after Hodgkin's disease. J Clin Oncol 2000; 18:765-72. [PMID: 10673517 DOI: 10.1200/jco.2000.18.4.765] [Citation(s) in RCA: 98] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To evaluate the incidence, detection, pathology, management, and prognosis of breast cancer occurring after Hodgkin's disease. PATIENTS AND METHODS Seventy-one cases of breast cancer in 65 survivors of Hodgkin's disease were analyzed. RESULTS The median age at diagnosis was 24.6 years for Hodgkin's disease and 42.6 years for breast cancer. The relative risk for invasive breast cancer after Hodgkin's disease was 4.7 (95% confidence interval, 3.4 to 6. 0) compared with an age-matched cohort. Cancers were detected by self-examination (63%), mammography (30%), and physician exam (7%). The histologic distribution paralleled that reported in the general population (85% ductal histology) as did other features (27% positive axillary lymph nodes, 63% positive estrogen receptors, and 25% family history). Although 87% of tumors were less than 4 cm, 95% were managed with mastectomy because of prior radiation. Two women underwent lumpectomy with breast irradiation. One of these patients developed tissue necrosis in the region of overlap with the prior mantle field. The incidence of bilateral breast cancer was 10%. Adjuvant systemic therapy was well tolerated; doxorubicin was used infrequently. Ten-year disease-specific survival was as follows: in-situ disease, 100%; stage I, 88%; stage II, 55%; stage III, 60%; and stage IV, zero. CONCLUSION The risk of breast cancer is increased after Hodgkin's disease. Screening has been successful in detecting early-stage cancers. Pathologic features and prognosis are similar to that reported in the general population. Repeat irradiation of the breast can lead to tissue necrosis, and thus, mastectomy remains the standard of care in most cases.
Collapse
MESH Headings
- Adolescent
- Adult
- Age Factors
- Aged
- Breast Neoplasms/diagnosis
- Breast Neoplasms/etiology
- Breast Neoplasms/genetics
- Breast Neoplasms/pathology
- Breast Neoplasms/therapy
- Breast Self-Examination
- Carcinoma, Ductal, Breast/etiology
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Ductal, Breast/secondary
- Carcinoma, Ductal, Breast/therapy
- Case-Control Studies
- Chemotherapy, Adjuvant
- Cohort Studies
- Confidence Intervals
- Female
- Follow-Up Studies
- Hodgkin Disease/therapy
- Humans
- Incidence
- Lymphatic Metastasis/pathology
- Mammography
- Mastectomy
- Middle Aged
- Neoplasms, Second Primary/diagnosis
- Neoplasms, Second Primary/etiology
- Neoplasms, Second Primary/pathology
- Neoplasms, Second Primary/therapy
- Physical Examination
- Prognosis
- Receptors, Estrogen/analysis
- Risk Factors
- Survival Rate
- Survivors
Collapse
Affiliation(s)
- S L Wolden
- Departments of Radiation Oncology, Medicine, and Surgery, Stanford University Medical Center, Stanford, CA, USA.
| | | | | | | | | | | |
Collapse
|
11
|
Abstract
The most common second primary tumors after treatment of childhood Hodgkin's disease are leukemia, lymphoma, breast cancer, soft tissue sarcoma, and thyroid cancer. Although intracranial meningioma has been reported after radiotherapy to the scalp for benign conditions and for intracranial primary brain tumors, this appears to be an extremely rare sequelae of treatment for Hodgkin's disease. The authors describe a 15-year-old boy who underwent radiotherapy for Hodgkin's disease and in whom a meningioma developed in the posterior fossa 27 years later.
Collapse
Affiliation(s)
- M Deutsch
- Department of Radiation Oncology, University of Pittsburgh Medical Center, Pennsylvania 15213, USA
| | | | | |
Collapse
|
12
|
Glanzmann C. [Malignant second tumors in patients after therapy of Hodgkin's disease at the Royal Marsden Hospital]. Strahlenther Onkol 1998; 174:224-5. [PMID: 9581188 DOI: 10.1007/bf03038535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
13
|
Cutuli B, de La Rochefordière A, Dhermain F, Borel C, Graic Y, de Lafontan B, Dilhyudy JM, Mignotte H, Tessier E, Tortochaux J, N'Guyen T, Bey P, Le Mevel-Le Pourhier A, Arriagada R. [Bilateral breast cancer after Hodgkin disease. Clinical and pathological characteristics and therapeutic possibilities: an analysis of 13 cases]. Cancer Radiother 1998; 1:300-6. [PMID: 9435820 DOI: 10.1016/s1278-3218(97)81497-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
PURPOSE Though Hodgkin's disease (HD) is one of the malignancies in which considerable progress has been made, long-term side effects have been observed, second primary cancer being the most significant. Several recent reports have indicated an increased risk of breast cancer (BC) in girls and young women among HD patients. MATERIALS AND METHODS In a retrospective multicenter analysis, 63 women treated for HD subsequently developed BC. Results that were obtained in 13 women (21%) who developed either synchronous (five cases) or metachronous (eight cases) BC were analyzed. The median age at diagnosis of HD was 19 years. Seven patients underwent exclusive radiotherapy (RT) (including "mantle" supradiaphragmatic irradiation) and six received concomittant radiation therapy and chemotherapy. RESULTS The first breast tumor occurred after a median delay of 16 years. According to the TNM classification, we showed nine stage T0 (non palpable lesions), four stage T1, five stage T2, one stage T3, two stage T4 and five stage Tx BC. Seventeen infiltrating carcinomas, two fibrosarcomas and seven ductal carcinomas in situ were observed. Among 15 axillary dissections performed for invasive carcinomas, histological involvement was found in 10 cases. Seventeen tumors were treated by mastectomy and nine patients underwent conservative surgical treatment. With a 70-month median follow-up (range: 15-125), three patients developed locoregional recurrence and four other metastases. At present, eight are alive with no evidence of disease and one died of intercurrent disease. CONCLUSION According to previous works, BC represents 6.3 to 9% of all second cancers occurring after HD treatment. The risk is higher in young women treated before 20 years of age, especially before 15 years of age. Factors that favour the development of secondary BC are: supradiaphragmatic irradiation, very young age at treatment, chemotherapy with alkylating agents, and probably genetic factors. We conclude that young women and girls treated for HD should be carefully monitored at least 10 years after the end of the treatment for HD, using clinical examination, mammography and ultrasonography. The optimal rythm of this follow-up is not yet clearly defined. Moreover, after multidisciplinary concertation, we suggest that secondary BC be sometimes treated by conservative radiosurgical approach.
Collapse
Affiliation(s)
- B Cutuli
- Département de radiothérapie, centre Paul-Strauss, Strasbourg, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Chung CT, Bogart JA, Adams JF, Sagerman RH, Numann PJ, Tassiopoulos A, Duggan DB. Increased risk of breast cancer in splenectomized patients undergoing radiation therapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1997; 37:405-9. [PMID: 9069314 DOI: 10.1016/s0360-3016(96)00498-1] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
PURPOSE Second malignancies have been reported among patients who were treated by radiation therapy or chemotherapy alone or in combination. Studies have implied an increased risk of breast cancer in women who received radiotherapy as part of their treatment for Hodgkin's disease. This review was performed to determine if there is an association between splenectomy and subsequent breast cancer. METHODS AND MATERIALS One hundred and thirty-six female patients with histologically proven Hodgkin's disease were seen in the Division of Radiation Oncology between 1962 and 1985. All patients received mantle or mediastinal irradiation as part of their therapy. The risk of breast cancer was assessed and multiple linear regression analysis was performed on the following variables: patient age, stage, dose and extent of radiation field, time after completing radiation therapy, splenectomy, and chemotherapy. RESULTS Breast cancer was observed in 11 of 74 splenectomized patients and in none of 62 patients not splenectomized. The mean follow-up was 13 years in splenectomized patients and 16 years, 7 months in nonsplenectomized patients. Nine patients developed invasive breast cancer and two developed ductal carcinoma in situ. Splenectomy was the only variable independently associated with an increased risk of breast cancer (p < 0.005) in multiple linear regression analysis; age, latency, and splenectomy considered together were also associated with an increased risk of breast cancer (p < 0.01). CONCLUSION Our data show an increased risk of breast cancer in splenectomized patients who had treatment for Hodgkin's disease. A multiinstitutional survey may better define the influence of splenectomy relative to developing breast cancer in patients treated for Hodgkin's disease. The risk of breast cancer should be considered when recommending staging laparotomy, and we recommend close follow-up examination including routine mammograms for female patients successfully treated for Hodgkin's disease.
Collapse
Affiliation(s)
- C T Chung
- Department of Radiation Oncology, State University of New York Health Science Center, Syracuse 13210, USA
| | | | | | | | | | | | | |
Collapse
|
15
|
Karasek K, Deutsch M. Lumpectomy and breast irradiation for breast cancer after radiotherapy for lymphoma. Am J Clin Oncol 1996; 19:451-4. [PMID: 8823472 DOI: 10.1097/00000421-199610000-00005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Six women received irradiation for lymphoma (Hodgkin's disease, n = 5; non-Hodgkin's disease, n = 1) to at least a mediastinal field (n = 2) or to a mantle field (n = 4), and subsequently developed breast cancer 10-27 years later. Three patients also received chemotherapy as a component of therapy for lymphoma. For breast cancer, all were treated with lumpectomy and breast irradiation to 5,000 cGy in 25 fractions plus a 1,000 cGy/5 fraction boost to the operative area using electrons. Two patients received adjuvant chemotherapy and three others tamoxifen for breast cancer. All women are alive and free of disease 15-118 months (median, 60 months) following breast irradiation. There have been no cases of significant acute reactions and no late sequelae such as skin pigmentation changes subcutaneous fibrosis, rib fractures, cardiac disease, or pulmonary fibrosis. The cosmetic result is considered good or excellent in all. Lumpectomy and breast irradiation is not contraindicated in the woman who develops breast cancer many years after irradiation of lymph node regions above the diaphragm for lymphoma.
Collapse
MESH Headings
- Adult
- Breast Neoplasms/etiology
- Breast Neoplasms/radiotherapy
- Breast Neoplasms/surgery
- Carcinoma, Ductal, Breast/etiology
- Carcinoma, Ductal, Breast/radiotherapy
- Carcinoma, Ductal, Breast/surgery
- Combined Modality Therapy
- Female
- Humans
- Lymphoma/radiotherapy
- Mastectomy, Segmental
- Mediastinal Neoplasms/radiotherapy
- Neoplasms, Radiation-Induced/etiology
- Neoplasms, Radiation-Induced/radiotherapy
- Neoplasms, Radiation-Induced/surgery
- Neoplasms, Second Primary/radiotherapy
- Neoplasms, Second Primary/surgery
- Radiotherapy/adverse effects
- Radiotherapy Dosage
Collapse
Affiliation(s)
- K Karasek
- Department of Radiation Oncology, University of Pittsburgh Medical Center, Pennsylvania 15213, USA
| | | |
Collapse
|
16
|
O'Brien PC, Barton MB, Fisher R. Breast cancer following treatment for Hodgkin's disease: the need for screening in a young population. Australasian Radiation Oncology Lymphoma Group (AROLG). AUSTRALASIAN RADIOLOGY 1995; 39:271-6. [PMID: 7487764 DOI: 10.1111/j.1440-1673.1995.tb00291.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Several recent publications have highlighted the issue of an increased risk of breast cancer in women treated with radiotherapy, chemotherapy, or combined modality therapy for Hodgkin's disease. The risk is greatest in women 30 years or younger at the time of treatment. In the Australasian Radiation Oncology Lymphoma Group database, 60% of women fell into this age category. This article reviews the available data pertaining to induction of breast cancer by radiotherapy for Hodgkin's disease. Breast examination should now be an integral part of the long term follow up for these women. There is also a case for the use of screening mammography. Any breast mass developing subsequent to treatment for Hodgkin's disease should be regarded with a high index of clinical suspicion and, accordingly, biopsies should be performed in the majority of cases, even when mammography is negative.
Collapse
Affiliation(s)
- P C O'Brien
- Radiation Oncology Department, Newcastle Mater Misericordiae Hospital, Waratah, Australia
| | | | | |
Collapse
|
17
|
Robinson BA, Colls BM, Fitzharris BM, Atkinson CH. Second malignant neoplasms in patients with Hodgkin's disease. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE 1994; 24:368-73. [PMID: 7980232 DOI: 10.1111/j.1445-5994.1994.tb01463.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
AIM To determine the incidence of second malignant neoplasms in patients treated for Hodgkin's disease. METHODS The records were reviewed of all patients receiving primary treatment for Hodgkin's disease at the Oncology Service, Christchurch Hospital from 1969 to 1992. Second malignant neoplasms presenting at least six months after the diagnosis of Hodgkin's disease were noted and the cumulative risk estimated. RESULTS Twenty-two second malignant neoplasms developed in 20 of the 209 patients. The risk was 5.6 +/- 3.8% (CI) at five years, 11.4 +/- 6.2% at ten years, and 21.7 +/- 11.2% at 15 years and continued to increase thereafter. Thirteen patients have died of their second malignancy, including two of a third malignancy, while four have been followed for less than one year. Three leukaemias (CML, 1; acute non lymphocytic leukaemia, 2), three lymphomas and 16 solid tumours developed. The risk was greater after six or more cycles of MOPP-like chemotherapy and after radiation doses exceeding 30 Gray. The risk was less after laparotomy and splenectomy (p = 0.0205). CONCLUSIONS In view of the significant risk of a second neoplasm in survivors of Hodgkin's disease follow up should continue beyond ten years, after which time second malignancies were more likely than recurrence. Efforts should continue to minimise the carcinogenicity of therapy while preserving efficacy.
Collapse
Affiliation(s)
- B A Robinson
- Oncology Service, Christchurch Hospital, New Zealand
| | | | | | | |
Collapse
|
18
|
Geffen DB, Krause I, Faermann S, Krutman Y, Vinograd L, Cohen Y. Bilateral synchronous breast carcinoma with axillary node involvement fifteen years after radiotherapy for Hodgkin's disease. Acta Oncol 1992; 31:477-8. [PMID: 1321651 DOI: 10.3109/02841869209088293] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
19
|
Abstract
The incidence of subsequent primary cancers was assessed in relation to treatment for a cohort of 7,203 patients from the Birmingham and West Midlands Cancer Registry diagnosed between 1957 and 1976. The total of 213 cancers observed one or more years after treatment for ovarian cancer (mean follow-up = 6.5 person-years) represented a significant excess (observed (O) = 213, expected (E) = 140.07, relative risk (RR) = 1.5, 95% CI 1.3-1.7, P less than 0.001). Among patients whose treatment included chemotherapy (CT), with or without radiotherapy (RT), the risk of acute and non-lymphocytic leukaemia (A + NLL) was significantly increased (O = 5, E = 0.18, RR = 27.8, 95% CI 9.0-64.8, P less than 0.001). The relative risks of A + NLL following RT without CT (RR = 4.5) and after other treatments (RR = 2.9) were not significantly in excess of 1.0. Significant excesses of subsequent cancers were observed at several sites: breast (RR = 1.7, 95% CI 1.3-2.2), lung (RR = 2.0, 95% CI 1.3-3.4), colon and rectum (RR = 1.6, 95% CI 1.1-2.3), urinary system (RR = 1.9, 95% CI 0.9-3.7), nervous system (RR = 3.3, 95% CI 1.2-7.3) and connective tissue (RR = 6.7, 95% CI 1.8-17.1) but the relationship with type of treatment was not so clearly defined as that for leukaemia. Although the treatment groups were broad and based on routinely collected data, they can enhance the use of cohort analyses for exploratory and monitoring purposes.
Collapse
Affiliation(s)
- P Prior
- Cancer Epidemiology Research Unit, Department of Social Medicine, University of Birmingham, UK
| | | |
Collapse
|